Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7276719 | 1.00 | CRHBP (0.44) | CRHBPCRHR2DGAT1DNMT1HCAR3 | |
| Water SCHEMBL10716192 | 0.99 | CRHBP (0.43) | CRHBPCRHR2DGAT1DNMT1HCAR3 | |
| Hydrochloric Acid SCHEMBL6371205 | 0.99 | CRHBP (0.43) | CRHBPCRHR2DGAT1DNMT1HCAR3 | |
| SCHEMBL7371470 | 0.91 | CRHBP (0.41) | CRHBPCRHR2HCAR3MAPTTDP1 | |
| SCHEMBL6370508 | 0.89 | MAPT (0.42) | CRHBPCRHR2HCAR3MAPTTDP1 | |
| SCHEMBL26934247 | 0.88 | MMP2 (0.43) | CRHBPCRHR2DGAT1HCAR3MAPT | |
| SCHEMBL14398078 | 0.88 | ERN1 (0.39) | DNMT1MAPTHTTALDH1A1KMT2A | |
| SCHEMBL11095621 | 0.82 | MMP2 (0.41) | CRHBPCRHR2HCAR3MAPTTDP1 | |
| SCHEMBL11095963 | 0.81 | MAPT (0.39) | CRHBPCRHR2HCAR3MAPTTDP1 | |
| SCHEMBL1799219 | 0.81 | KMT2A (0.43) | MAPTTDP1KDM4EHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105168130-B | A kind of tumour target polymer micella and preparation method thereof | 安徽医科大学 | 2017-10-27 | — | — | CN | disclosed |
| CN-1125818-C | Amino acid derivatives of substituted quinoxaline 2, 3 -dione derivativesa as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 2003-10-29 | — | — | CN | disclosed |
| US-6455698-B1 | FOR TREATING CEREBRAL ISCHEMIA OR CEREBRAL INFARCTION RESULTING FROM THROMBOEMBOLIC OR HEMORRHAGIC STROKE, CEREBRAL VASOSPASMS, HYPOGLYCEMIA, CARDIAC ARREST, NEURODEGENERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2002-09-24 | — | — | US | disclosed |
| EP-0832074-B1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | KORNBERG BRIAN EDWARD (US) | 2002-05-30 | — | — | US | disclosed |
| US-6340758-B1 | DRUGS AS NEUROPROTECTIVE AGENTS INVENTION MAY ALSO BE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, EPILEPSY, ANXIETY, PAIN AND DRUG ADDICTION. | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-6268366-B1 | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| US-6191134-B1 | STROKE THERAPY, ANTIISCHEMIC AGENTS, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2001-02-20 | — | — | US | disclosed |
| CN-1187190-A | Amino acid derivatives of substituted quinoxaline 2, 3-dione derivatives as glutamate receptor antagonists | WARNER LAMBERT CO (US) | 1998-07-08 | — | — | CN | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| WO-1996040649-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996000738-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0675902-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-10-11 | — | — | EP | disclosed |
| EP-0647236-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994014843-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1993021219-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1992020706-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0377139-A1 | N-substituted acylamino acid compounds, process for their production and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1990-07-11 | — | — | EP | disclosed |
| EP-0210545-A2 | Phosphorous containing enzyme inhibitors | MERCK & CO. INC. (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065415-A1 | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents | CBR1, CBR3, CHRNA7 | CRHBP 2335/4885CRHR2 100/4885DGAT1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.